Research Analysts Offer Predictions for ARCT FY2025 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Research analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of Arcturus Therapeutics in a research report issued on Tuesday, November 11th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings per share of ($1.88) for the year, up from their prior estimate of ($3.89). HC Wainwright has a “Neutral” rating and a $9.00 price objective on the stock. The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. HC Wainwright also issued estimates for Arcturus Therapeutics’ Q4 2025 earnings at ($0.53) EPS, Q1 2026 earnings at ($0.71) EPS, Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.66) EPS, Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($2.19) EPS, FY2027 earnings at ($2.61) EPS, FY2028 earnings at ($1.48) EPS and FY2029 earnings at $1.72 EPS.

ARCT has been the topic of several other research reports. Wall Street Zen lowered Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 25th. Citigroup lowered shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $49.00 to $12.00 in a report on Thursday, October 23rd. Zacks Research cut Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Wells Fargo & Company lowered their price target on shares of Arcturus Therapeutics from $42.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, October 23rd. Finally, BTIG Research reduced their price objective on shares of Arcturus Therapeutics from $48.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, October 22nd. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $36.38.

Arcturus Therapeutics Stock Performance

Shares of ARCT stock traded down $0.01 during trading hours on Thursday, reaching $8.12. The company had a trading volume of 168,080 shares, compared to its average volume of 678,932. Arcturus Therapeutics has a 12-month low of $7.91 and a 12-month high of $24.17. The company has a market capitalization of $220.65 million, a price-to-earnings ratio of -3.30 and a beta of 2.47. The stock has a fifty day moving average of $16.58 and a 200-day moving average of $14.67.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.60. Arcturus Therapeutics had a negative net margin of 68.35% and a negative return on equity of 28.35%. The firm had revenue of $17.15 million for the quarter, compared to the consensus estimate of $17.47 million.

Institutional Trading of Arcturus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC acquired a new position in Arcturus Therapeutics in the first quarter valued at $4,892,000. Vestal Point Capital LP acquired a new position in shares of Arcturus Therapeutics in the first quarter valued at approximately $2,243,000. Diversify Advisory Services LLC raised its position in Arcturus Therapeutics by 1,136.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 222,500 shares of the biotechnology company’s stock worth $2,895,000 after buying an additional 204,500 shares during the last quarter. ARK Investment Management LLC boosted its stake in shares of Arcturus Therapeutics by 9.2% in the third quarter. ARK Investment Management LLC now owns 1,872,721 shares of the biotechnology company’s stock valued at $34,514,000 after buying an additional 157,681 shares in the last quarter. Finally, Amova Asset Management Americas Inc. lifted its holdings in Arcturus Therapeutics by 6.4% in the third quarter. Amova Asset Management Americas Inc. now owns 1,947,835 shares of the biotechnology company’s stock valued at $35,879,000 after acquiring an additional 117,632 shares during the period. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.